1118767-15-9 Semaglutide intermediate
Product name: Semaglutide intermediate
CAS number: 1118767-15-9
Molecular formula: C47H82N4O15
Molecular weight: 943.17
EINECS number:
MDL No.:MFCD32661370
Application:
tBuO-Ste-E(AEEA-AEEA-OSu)-OtBu can be used as a pharmaceutical intermediate, Semaglutide intermediate
| Downstream Application Field | Specific Products | Product Description |
|---|---|---|
| Pharmaceutical Synthesis (Anti-diabetic & Weight-loss Drugs) | Semaglutide API, GLP-1 receptor agonist derivatives, long-acting antidiabetic drugs, obesity treatment medications | Semaglutide side chain (NHS-activated ester) acts as a core side chain building block for synthesizing semaglutide, a first-in-class long-acting GLP-1 receptor agonist. Its NHS-activated ester group enables efficient amidation coupling with the semaglutide peptide backbone, while the polyether chain (4,7,10,13-tetraoxa-hexadecane segment) confers long-circulating properties (prolonged half-life via albumin binding) to the final API. It is exclusively used in manufacturing semaglutide for treating type 2 diabetes mellitus (T2DM) and obesity, as the side chain enhances the drug's pharmacokinetic profile (once-weekly administration) and target selectivity for pancreatic β-cells and hypothalamic appetite centers. |
| Advanced Peptide Drug Intermediates | Modified GLP-1 receptor agonist side chains, long-circulating peptide linkers, NHS-activated polyether-amino acid conjugates | It serves as a precursor for synthesizing advanced peptide drug intermediates. Through structural modifications (e.g., polyether chain length adjustment, functional group substitution, linker optimization), it can be converted into side chains for next-generation GLP-1 agonists (e.g., tirzepatide analogs, dual GLP-1/GIP receptor agonists). These derivatives are designed to improve drug efficacy, reduce injection frequency, or expand therapeutic indications (e.g., non-alcoholic steatohepatitis (NASH)). |
| Drug Discovery & R&D | GLP-1 receptor agonist compound libraries, long-acting peptide drug prototypes, structure-pharmacokinetic relationship (SPR) research tools | High-purity grades are used in pharmaceutical R&D laboratories and biotech companies. They are employed to construct GLP-1 receptor agonist libraries for high-throughput screening (HTS), optimize structure-pharmacokinetic relationships (SPR) of long-acting peptide drugs, and develop novel dual/triple receptor agonists (GLP-1/GIP/GLUC). The compound's unique polyether-NHS side chain scaffold provides a template for designing long-circulating peptide drugs with improved pharmacodynamics and patient compliance. |
| Biomedical Research | Peptide-drug conjugation (PDC) tools, albumin-binding peptide probes, GLP-1 receptor interaction research reagents | In biomedical research, it is used to synthesize albumin-binding peptide probes and peptide-drug conjugates (PDCs) for studying GLP-1 receptor signaling pathways, peptide-albumin binding mechanisms, and drug distribution in vivo. It also serves as a tool compound for investigating the correlation between side chain structure and the long-acting properties of peptide drugs, providing critical insights for preclinical development of metabolic disease therapeutics. |
Synonyms:
1118767-15-9
Octa(OtBu)-Glu(AEEA-AEEA-OSu)-OtBu
21,39-DI-TERT-BUTYL 1-(2,5-DIOXOPYRROLIDIN-1-YL) (S)-9,18,23-TRIOXO-2,5,11,14-TETRAOXA-8,17,22-TRIAZANONATRIACONTANE-1,21,39-TRICARBOXYLATE
tert-butyl 17-{[1-(tert-butoxy)-4-({2-[2-({[2-(2-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethoxy}ethoxy)ethyl]carbamoyl}methoxy)ethoxy]ethyl}carbamoyl)-1-oxobutan-2-yl]carbamoyl}heptadecanoate
Package:
Inner packaging: transparent plastic bag+aluminum foil bag; Outer packaging: cardboard box or cardboard drum
Hot Tags: 1118767-15-9 Semaglutide intermediate, China 1118767-15-9 Semaglutide intermediate manufacturers, suppliers, plastic molding intermediate, packaging intermediate, research intermediate, rubber compounding intermediate, emerging market intermediate, intermediate pharmaceutical products


